ArticlePrzeglad gastroenterologiczny2025
Stem cell therapy for chronic diffuse liver lesions: main symptoms and causes.
Article in Przeglad gastroenterologiczny, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic liver damage is one of the most important and complex problems in modern gastroenterology. The relevance of studying chronic hepatitis of various aetiologies is associated with its high socio-economic and medical significance due to the steady progressive course, with the development of fibrosis, and then cirrhosis of the liver. Aim: The purpose of this study was to search for and analyse new biotechnological methods for the treatment of diffuse liver diseases to improve patient survival, since the main contingent of patients is typically the able-bodied, socially active part of the population. Material and methods: To achieve this goal, general theoretical methods of scientific knowledge were used, such as analysis, generalization, questioning, and systematization. Results: The article presents a meta-analysis of the results of studies conducted in the field of cellular technologies by leading scientists in the field of the treatment of liver diseases. The issues of transdifferentiation, the mechanisms of action of stem cells in hepatology, as well as the possible risks of this therapy (pro-oncogenic effect, increased fibrosis), are covered. Conclusions: Cell therapy in embryonic, mononuclear, and mesenchymal stromal cells is the most advanced area of modern biotechnology and medicine. Its therapeutic application in chronic liver diseases is base on the possibility of regulating disturbed intercellular interactions in the liver, influencing the mechanisms of cell death (necrosis, apoptosis) and fibrogenesis, which makes this method the most relevant and promising in hepatology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.